ImmuCell Corporation Achieves Record-Breaking $10 Million Revenue Quarter, Shows Confidence in Strategic Focus on Calf Scours Market
On May 15, 2026, ImmuCell Corporation hosted a conference call to discuss its unaudited first quarter 2026 financial results. The company reported a significant milestone, achieving its first-ever $10 million revenue quarter, marking an exciting achievement for the commercial team and manufacturing team.
The $10.4 million in product sales for the first quarter of 2026 represents a 28.4% increase compared to the record-breaking first quarter of 2025. Domestic sales grew by 35.7% to approximately $9.7 million, while international sales declined by 30.2% to about $600,000 during the same period.
The company's focus on the calf scours market, evident in its strategic efforts to improve manufacturing yield and leadership, has started to show results. The gross margin improved significantly, reaching 45% after absorbing legacy Re-Tain-related costs that reduced margins by approximately 2.4% during the quarter. This improvement in gross margin demonstrates the company's ability to manage costs effectively.
Net income grew by a substantial 34% compared to the first quarter of 2025, indicating a strong financial performance for ImmuCell Corporation. The company's confidence in its strategic focus is clear, as Olivier te Boekhorst, President and Chief Executive Officer, highlighted during the conference call.
ImmuCell's decision to focus on its successful on-market product, First Defense, has shown positive results. The company believes it is gaining share in the market against larger competitors. Historically, challenges have centered around manufacturing capacity and product availability; however, the recent results demonstrate progress towards solving these issues.
The strong performance of Tri-Shield, ImmuCell's flagship product, with a 38.5% growth in sales compared to the first quarter of 2025, is also notable. This indicates that the company's strategic efforts are paying off and will likely continue to drive revenue growth.
With these encouraging results, it appears ImmuCell Corporation has made significant strides towards establishing itself as a leader in the calf scours market. As the company continues to focus on solving manufacturing capacity and product availability challenges, investors can expect even more exciting developments from this innovative organization.
